Severe aplastic anemia (SAA) is a rare, life-threatening blood disorder in which the bone marrow nearly stops producing new blood cells. The marrow, which normally churns out red cells, white cells, and platelets, becomes abnormally empty. Without treatment, the resulting shortage of all three cell types can be fatal within months, primarily from uncontrolled infections or bleeding. With modern therapies, though, outcomes have improved dramatically: patients who survive the first year after treatment now have long-term survival rates comparable to the general population.
What Happens Inside the Bone Marrow
In most cases of severe aplastic anemia, the damage is self-inflicted by the immune system. The body’s own immune cells, specifically a type of white blood cell designed to kill threats, mistakenly target the stem cells that produce all blood components. Something triggers this attack, possibly a virus, a drug, or a chemical exposure, but in a genetically susceptible person the immune response spirals out of control instead of shutting down once the threat is gone.
These rogue immune cells do their damage in two ways. They directly kill stem cells by latching onto them and triggering programmed cell death. They also flood the bone marrow with inflammatory signals that suppress any remaining stem cells from growing and dividing. In lab studies, immune cells taken from untreated patients killed up to 75% of bone marrow cells when the two were mixed together. The end result is a bone marrow that’s less than 25% as full as it should be, leaving it unable to replenish the blood supply.
Known Triggers and Causes
The immune attack at the heart of SAA doesn’t come out of nowhere, though in many patients the exact trigger is never identified. Recognized causes include autoimmune disorders (the most common association), viral infections such as hepatitis, Epstein-Barr virus, or HIV, toxic chemical exposures like benzene, pesticides, and arsenic, and reactions to certain medications. In rare cases, aplastic anemia is inherited rather than acquired, stemming from genetic conditions that leave stem cells fragile from birth. But the acquired, immune-driven form accounts for the vast majority of cases.
How It Feels: Symptoms of SAA
Because all three major blood cell lines drop simultaneously, SAA produces overlapping symptoms that can worsen quickly. Low red blood cells cause fatigue, weakness, dizziness, pale skin, and a noticeably fast heartbeat, especially with exertion. Low platelets lead to easy bruising, tiny pinpoint red spots on the skin called petechiae, and bleeding from the gums or nose that’s hard to stop. Low white blood cells, particularly infection-fighting neutrophils, leave you vulnerable to bacterial and fungal infections that a healthy immune system would handle easily.
One counterintuitive detail: at the time of diagnosis, many patients don’t show obvious signs of infection even though their white cell counts are dangerously low. The risk is there, but visible infection often appears later, especially if treatment is delayed. This is part of what makes SAA deceptive. Fatigue and bruising can seem minor at first, but the underlying blood counts may already be critically low.
How Severe Aplastic Anemia Is Diagnosed
Diagnosis starts with a complete blood count, but the specific thresholds that define “severe” are precise. SAA requires a bone marrow biopsy showing cellularity below 25% of normal, plus at least two of three blood count criteria: neutrophils below 500 per microliter, platelets below 20,000 per microliter, or a very low reticulocyte count (reticulocytes are immature red blood cells, and their absence means the marrow isn’t even trying to produce new ones).
There’s also a category called very severe aplastic anemia, which uses the same criteria except neutrophils must be below 200 per microliter. That distinction matters because it affects treatment urgency and prognosis. Moderate aplastic anemia, by contrast, involves depressed blood counts that don’t reach these severe thresholds. The bone marrow biopsy is essential because other conditions, including leukemia and certain vitamin deficiencies, can mimic the blood test findings.
Treatment: Transplant vs. Immune Therapy
Two main treatment paths exist, and the choice between them depends largely on your age and whether you have a matched sibling donor available for a stem cell transplant.
Stem Cell Transplant
A transplant from a matched sibling donor is the most effective option, especially for younger patients. Three-year survival rates from a large European registry study paint a clear picture of how age and donor type influence outcomes. Children under 18 with a matched sibling donor had a 93% three-year survival rate. For adults aged 18 to 40, that figure was 87%. It dropped to around 70% for those in their 40s and 50s, and to 59% for patients over 60.
When no matched sibling is available, transplants from unrelated donors or partially matched family members are possible but carry higher risks. Three-year survival with a matched unrelated donor was 89% for children and 81% for young adults, still strong numbers. Transplants from partially matched (haploidentical) donors showed lower survival across all age groups, with rates ranging from 67% in children to as low as 15% in patients over 60.
Immunosuppressive Therapy
For patients who aren’t candidates for a transplant, the standard first-line treatment uses a combination of drugs to shut down the immune attack. The backbone has traditionally been horse-derived anti-thymocyte globulin (a protein that destroys the rogue immune cells) combined with cyclosporine (which prevents new immune attacks). A landmark trial comparing horse-derived and rabbit-derived versions of this therapy found a striking difference: 68% of patients responded to horse ATG at six months, compared to only 37% with rabbit ATG. Three-year survival was 96% with horse ATG versus 76% with rabbit ATG. Horse ATG is now the clear standard.
More recently, adding a drug that stimulates the bone marrow to produce more blood cells has improved results further. A phase 3 trial published in the New England Journal of Medicine showed that combining this oral medication with standard immunosuppressive therapy improved the speed, rate, and strength of blood count recovery in previously untreated patients, without additional side effects. This triple-drug approach has become the modern standard for patients receiving immune-based therapy rather than transplant.
Long-Term Outlook and Complications
The prognosis for SAA has improved substantially over the past two decades. Patients who survive the first year after either transplant or immunosuppressive therapy can generally expect to live five, ten, or more years with survival rates approaching those of the general population. For transplant recipients, a successful engraftment is essentially curative, as the new donor marrow replaces the patient’s defective immune and blood-forming system entirely.
Immunosuppressive therapy, while highly effective, is not considered a cure in the same way. The underlying vulnerability of the bone marrow persists, and about 15% of patients treated with immune therapy eventually develop a secondary blood cancer, typically a form of pre-leukemia (myelodysplastic syndrome) or acute leukemia, often years after the original diagnosis. Around half of all aplastic anemia patients also show evidence of a related condition called paroxysmal nocturnal hemoglobinuria (PNH), in which mutated stem cells expand to fill the gap left by the immune attack. PNH can cause episodes of dark urine, blood clots, and additional anemia, though many patients with small PNH clones never develop symptoms.
These risks mean that even patients who respond well to immunosuppressive therapy need ongoing blood count monitoring for years. About 20% of patients initially treated with immune therapy eventually require a stem cell transplant because their response was incomplete or their blood counts declined again. Still, for patients who reach the five-year mark after treatment, long-term survival now looks remarkably close to normal.